Immuno-Oncology

Toward more predictive preclinical tumor mouse models: conventional tumor models with immunodeficient animals only monitor the effect of a drug on the tumor itself. The approval in 2011 of the first immune-checkpoint inhibitor (Nobel price winner in 2018) has validated the immuno-oncology therapeutic approach against many forms of cancer. The reconstitution of the full functional human immune system in immune-deficient triple KO mice such as NOG/NCG/NSG/BRG provides a unique opportunity to assess the efficacy of new drug candidates acting on both human immune cells such as T cells, myeloid cells and NK cells, and on the tumor itself (bi-specific mAb, ADCC mediation, …) with either Solid (Melanoma, breast, ovarian,…) or Liquid (T-cell lymphoma, B-cell Lymphoma, AML) tumors.

DATA Driven with more than

studies completed

Immune Check Point Inhibitor

Hu-mouse engrafted with Gastric Tumor Cells
Treatment with Anti-PD1
Combo Therapy tested in the same setting

Combination Therapies

Immune Cell Infiltration
IHC

Hu-mouse engrafted with Gastric tumor cells
Immune infiltration (CD8 staining)

Immune Cell Infiltration
Flow Cytometry

Automated mechanic and enzymatic digestion of human tumors
Flow Cytometry analysis on whole tumor

Oncolytic Virus Efficacy in hu-mouse

Colon carcinoma. Treatment with oncolytic virus (intra-tumor vs i.v. injection)

Bi-Specific Ab with ADCC activity

Hu-mouse engrafted with HCT-116 colorectal cancer cells
Treatment with Bi-specific Ab
ADCC activity

T Cell Immunity – Vaccination

Hu-mouse vaccinated against Mart-1 peptide
Cellular response in the peripheral blood 28 days after vaccination
Tetramer Staining of CD8+ cells

Mart-1 peptide vaccination, flow cytometry on peripheral blood and assessment effector CD8+ T cells

Transient Boost with human Cytokines

Readout:

TILs
Peripheral blood immuno-phenotyping
Tumor growth: caliper & in vivo imaging
Survival
In vitro analysis: Elisa – Elispot – Slpenocyts restimulation
Safety and Cytokines Storm analysis – CBA

List of Tumor Cell lines

PDX – Studies

Strength of TransCure bioServices in cancer/immuno-Oncology/PDX

>3’000 hu-mouse tested for cancer/immuno-oncology/PDX
Human cytokine boosts available upon request
Validated models for: immune checkpoint inhibitors, PDX, oncolytic viruses, ADCC, vaccines
Ideal for combination strategy
Expertise in protocol/study design/endpoints with hu-mouse
Quality raw data collection and report analysis
Time and cost-saving, competitive FTE rate